Ono Pharmaceutical Co., Ltd.
OPHLYOTCHealthcare● Active
$4.63
+$0.08(+1.76%)
Market Cap$6.5B
P/E Ratio—
52W High$5.75
52W Low$3.35
Ono Pharmaceutical Co., Ltd. (OPHLY) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · OPHLY · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $546.89B | $486.87B | $502.67B | $447.19B | $361.36B |
| Cost of Revenue | $150.26B | $147.95B | $127.13B | $110.06B | $93.51B |
| Gross Profit | $396.63B | $338.92B | $375.55B | $337.13B | $267.85B |
| Gross Margin %(computed) | 72.52% | 69.61% | 74.71% | 75.39% | 74.12% |
| Operating Expenses | |||||
| R&D Expenses | $155.91B | $149.87B | $112.38B | $95.34B | $75.88B |
| G&A Expenses | $0.00B | $91.57B | $73.37B | $68.81B | $62.62B |
| Total Operating Expenses | $287.06B | $279.17B | $212.44B | $195.16B | $164.65B |
| Operating Income | $109.57B | $59.75B | $163.10B | $141.96B | $103.19B |
| Operating Margin %(computed) | 20.03% | 12.27% | 32.45% | 31.75% | 28.56% |
| Interest Income | $4.19B | $4.77B | $4.03B | $2.48B | $2.71B |
| Interest Expense | $3.75B | $5.32B | $0.23B | $0.91B | $0.87B |
| Income Before Tax | $98.24B | $59.33B | $163.73B | $143.53B | $105.03B |
| Income Tax Expense | $24.11B | $9.16B | $35.69B | $30.62B | $24.34B |
| Net Income | $73.97B | $50.05B | $127.98B | $112.72B | $80.52B |
| Net Margin %(computed) | 13.53% | 10.28% | 25.46% | 25.21% | 22.28% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $52.73 | $35.52 | $88.86 | $76.94 | $54.06 |
| Wtd Avg Shares | 1.41B | 1.41B | 1.44B | 4.40B | 4.47B |
| EBITDA | $149.60B | $91.54B | $178.44B | $161.90B | $123.62B |
| EBITDA Margin %(computed) | 27.35% | 18.80% | 35.50% | 36.20% | 34.21% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · JPY · B
Explore more Ono Pharmaceutical Co., Ltd. data
About Ono Pharmaceutical Co., Ltd. (OPHLY) Income Statement
Ono Pharmaceutical Co., Ltd. (OPHLY) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2026, OPHLY reported revenue of $546.89B, gross profit of $396.63B (gross margin 72.52%), and net income of $73.97B — a net profit margin of 13.53%.
Frequently asked questions
OPHLY · 4 questionsOno Pharmaceutical Co., Ltd. (OPHLY) reported revenue of $546.89B for 2026, up 12.3% year-over-year.
OPHLY revenueOPHLY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09